Esperion Therapeutics ESPR Common stock, shares authorized (in shares)
Common stock, shares authorized (in shares) at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's common stock, shares authorized (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's common stock, shares authorized (in shares)?
- Esperion Therapeutics (ESPR) reported common stock, shares authorized (in shares) of $480M in Q1 2026.
- How has Esperion Therapeutics's common stock, shares authorized (in shares) changed year-over-year?
- Esperion Therapeutics's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $480M to $480M.
- What is the long-term trend for Esperion Therapeutics's common stock, shares authorized (in shares)?
- Over 5 years (2020 to 2025), Esperion Therapeutics's common stock, shares authorized (in shares) has grown at a 32.0% compound annual growth rate (CAGR), from $120M to $480M.